Paula Freitas

ORCID: 0000-0002-8732-8046
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bariatric Surgery and Outcomes
  • Diet and metabolism studies
  • HIV-related health complications and treatments
  • Pituitary Gland Disorders and Treatments
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Healthcare during COVID-19 Pandemic
  • Youth, Drugs, and Violence
  • Cardiovascular Disease and Adiposity
  • Diabetes and associated disorders
  • Nuclear Structure and Function
  • Diabetes Management and Research
  • Liver Disease Diagnosis and Treatment
  • Growth Hormone and Insulin-like Growth Factors
  • Body Contouring and Surgery
  • Health and Lifestyle Studies
  • Adrenal Hormones and Disorders
  • Diabetes Management and Education
  • Diabetes Treatment and Management
  • Metabolism, Diabetes, and Cancer
  • Gut microbiota and health
  • Adrenal and Paraganglionic Tumors
  • Healthcare Regulation
  • HIV Research and Treatment
  • Vitamin D Research Studies
  • Bone health and osteoporosis research

Universidade do Porto
2016-2025

Hospital de São João
2016-2025

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2015-2024

Administração Regional de Saúde de Lisboa e Vale do Tejo
2024

Centro Hospitalar do Porto
2018-2023

Diabetes Australia
2012-2023

Faculdade de Medicina do ABC
2015-2022

Sociedade Portuguesa de Cardiologia
1999-2022

Universidade Estadual Paulista (Unesp)
2011-2017

Universidad Santa María
2017

The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people overweight or obesity is unknown.To compare continued once-weekly subcutaneous 2.4 mg, switch to placebo for (both lifestyle intervention) adults after 20-week run-in semaglutide titrated mg weekly.Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites 10 countries from June 2018 March 2020 body mass index least 30 (or...

10.1001/jama.2021.3224 article EN JAMA 2021-03-23

Intestinal fatty-acid binding protein (I-FABP) is expressed in epithelial cells of the mucosal layer small intestine tissue. When intestinal damage occurs, I-FABP released into circulation and its plasma concentration increases. In context obesity, gut barrier integrity can be disrupted by dietary fat while permeability increases.To investigate whether fatty acid a suitable marker injury inflammation obesity.Twelve male Wistar rats were randomly divided two groups six animals each: standard...

10.1186/s12986-016-0089-7 article EN cc-by Nutrition & Metabolism 2016-04-30

Gut microbiota dysbiosis has been recognized as having key importance in obesity- and metabolic-related diseases. Although there is increasing evidence of the potential benefits induced by probiotics metabolic disturbances, a lack large cross-sectional studies to assess population-based prevalence probiotic intake Our aim was evaluate association ingestion with obesity, type 2 diabetes, hypertension, dyslipidemia. A study designed using data from National Health Nutrition Examination Survey...

10.3390/nu11071482 article EN Nutrients 2019-06-28

<b><i>Introduction:</i></b> Bariatric surgery is an effective treatment for morbid obesity and its metabolic related comorbidities. However, the literature reports inconsistent results regarding weight loss (WL) resolution of comorbidities associated with obesity. <b><i>Objective:</i></b> We aim to evaluate long-term differences in WL between different surgical techniques impact each technique on parameters (type 2 diabetes mellitus [T2DM],...

10.1159/000503753 article EN cc-by-nc-nd Obesity Facts 2019-01-01

In HIV-infected patients, combination antiretroviral therapy (cART) is associated with clinical lipodystrophy (CL) and metabolic abnormalities (MA). This study aimed to evaluate the prevalence of syndrome (MS) its components, determine whether patients or without CL had a different MA. We evaluated 345 on cART using two MS definitions (NCEP-ATPIII-2005 IDF-2005) Framingham risk score. was present in 58.7% patients. The 52.2% (ATPIII) 43.2% (IDF), it not significantly between (W) (WT) CL,...

10.1186/1471-2334-11-246 article EN cc-by BMC Infectious Diseases 2011-09-20

Lipodystrophies are characterized by adipose tissue redistribution, insulin resistance (IR) and metabolic complications. Adipokines hormones related to body composition may play an important role linking these alterations. Our aim was evaluate adipocyte-derived (adiponectin, leptin, resistin, TNF-α, PAI-1) ghrelin plasma levels their relationship with IR in HIV-infected patients according the presence of lipodystrophy fat redistribution.Anthropometric parameters, HOMA-IR, DXA CT, adipokines...

10.1186/1471-2334-14-347 article EN cc-by BMC Infectious Diseases 2014-06-23

The prevalence of hypogonadism in HIV-infected patients is still a matter debate as there no standardized consensual diagnostic method. In addition, the etiology and endocrine/metabolic implications this population remain controversial. This study aims to determine testosterone deficiency single-site hospital evaluate its association with potential risk factors, lipodystrophy, metabolic syndrome, cardiovascular risk. analyzed 245 men on combined antiretroviral therapy. Patients low total...

10.1186/s12879-016-1892-5 article EN cc-by BMC Infectious Diseases 2016-11-03

Antiretroviral therapy dramatically reduced HIV-related morbidity and mortality, prolonging the lifespan of HIV-infected patients. Greater duration infection exposure to antiretroviral makes these patients susceptible traditional cardio-metabolic risk factors pathologies. The optimal diagnostic protocol for Diabetes Mellitus in is still controversial. Haemoglobin A1c (HbA1c) has been shown underestimate glycaemia levels oral glucose tolerance test (OGTT) reveal cases metabolism disturbances...

10.1186/s12879-018-3221-7 article EN cc-by BMC Infectious Diseases 2018-07-06

Abstract Introduction Bariatric surgery is recognized as the most effective long-term treatment for clinically severe obesity, leading to sustained weight loss. Among common bariatric procedures, laparoscopic Roux-en-Y gastric bypass (RYGB) frequently performed and known its significant loss results ability reduce obesity-related comorbidities in many patients. However, 10% 40% of patients may experience insufficient (IWL) or regain (WR), along with persistence recurrence after 5 7 years,...

10.1093/bjs/znaf036.078 article EN British journal of surgery 2025-02-01

Abstract Background Obesity is rapidly emerging as a significant epidemic in developing countries. Although promising therapeutics are development, bariatric surgery remains the most effective treatment. To better characterize this disease, waist and hip circumference measurements, waist-to-hip ratio were developed. These measures provide valuable insights into body fat distribution its associated health risks, enabling more accurate assessments targeted interventions. Methods A...

10.1093/bjs/znaf036.065 article EN British journal of surgery 2025-02-01

Abstract Introduction Laparoscopic Roux-En-Y gastric bypass (LRYGB) is one of the most performed procedures for morbid obesity. Morbidity and mortality associated with bariatric surgery are considered low. Nevertheless, post-operative haemorrhage frequent early complication after LRYGB. Methods We conducted a retrospective cohort study regarding all patients submitted to LRYBG between 2019 2023 at our centre. Postoperative was defined as clinically significant evidence bleeding in...

10.1093/bjs/znaf036.036 article EN British journal of surgery 2025-02-01
Coming Soon ...